Running head: A system for remote dosimetry audit
Introduction
The introduction of advanced treatment techniques such as intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) has introduced new challenges for dosimetry audits and also increased the importance of auditing. The two largest audit networks are currently operated by the IAEA [1, 2] and the Imaging and Radiation Oncology Core Huston (IROC Huston) [3] .
Electron paramagnetic resonance (EPR) dosimetry using alanine is an accepted standard dosimetric method and has been used for audits in the UK [4] , Italy [5] and Belgium [6] . The readout process for EPR dosimeters is non-destructive to the signal which allows several readouts of the same dosimeter.
Lithium formate is thoroughly investigated and has dosimetric properties at least as good as those of alanine. Both lithium formate and alanine has a linear dose response in a large dose region (0.2 Gy -found in the literature focus on dose determination in absolute terms solely at the isocentre. However, the doses to organs at risk (OARs) are equally important to verify, since they normally set the limit for the target dose. Compared to alanine, lithium formate has an even better water equivalence regarding mass-energy absorption and mass collision stopping power and also up to seven times higher sensitivity [7, 8] . The lithium formate system is robust; the signal is stable at least one month after irradiation (a sufficient time period for audit measurements) and not affected by variations in storage temperature [9] .
The response is independent of dose rate and beam quality in the MV energy region [10] . Lithium formate has previously been used for verification of IMRT treatments [10] and for measurement around 192 Ir brachytherapy sources [11] . The LET-dependence of response for photon energies < 150 keV relative to 60 Co is known [12] and imply that the lithium formate system is a good candidate for use also in brachytherapy audits.
The aim of this work was to develop and evaluate a remote end-to-end audit system for high energy external beam therapy using lithium formate EPR dosimeters with determination of doses in absolute terms in target and OARs for 3D-CRT, IMRT and VMAT. The system was tested in a pilot study at four clinics in Sweden. A future aim is to participate in developing a system for quality improvements of radiotherapy that can serve useful in fulfilling upcoming national regulatory requirements on regular, independent dosimetric audits.
Material and methods

Dosimeters and EPR readout
The cylindrical dosimeters pressed to a height of 4.8 mm and diameter 4.5 mm consist of 90% lithium formate and 10% paraffin used as a binder. A BRUKER EleXsys E500 was used with a BRUKER standard resonator (4102ST) for all readouts. Details about the dosimeter manufacturing and handling can be found in earlier publications [10] [11] [12] .
Phantom
A semi-anthropomorphic head-and-neck phantom was designed with inspiration from Han et al. [13] , in this pilot test was restricted to include a certain number of fields, energies, wedges etc. The planned dose to the PTV was set to 2 Gy to be delivered twice, a 4 Gy total dose to achieve high EPR signal to noise ratio. The standard 2 Gy per fraction was chosen to keep the multi-leaf collimator (MLC) speed clinically relevant. The institutions were asked to report the planned doses together with the daily output of the particular beam used for irradiation.
Uncertainty budget and acceptance criteria
Absorbed dose to water determined by the dosimeters has a combined standard uncertainty of 2%-2.5%.
The main contributing factor is the type B uncertainty of the ionization chamber used for calibration of the dosimeters (1.7%) [14] , other factors are related to the readout process and the homogeneity within the dosimeter batch. According to a review by Ahnesjö and Aspradakis [15] , the relative standard uncertainty in the treatment planning system (TPS) dose calculation is approximately 2% (k=1). Thus, the relative combined standard uncertainty of the percentage deviation between measured and calculated doses is 3% (k=1) [16] . This uncertainty level was considered sufficient to set a preliminary acceptance criterion of 5% for 3D-CRT. The dose calculation, planning and delivery of IMRT and VMAT are more complex compared to 3D-CRT and are associated with larger uncertainty [17] . Thus, the preliminary acceptance was set to 7% for IMRT and VMAT.
Results and discussion
Results from the pilot study are shown in figures 2 (3D-CRT) and 3 (IMRT, VMAT). ±7% but some close to the acceptance limit. This irradiation should preferably be repeated to determine the reproducibility in the result before any conclusions can be drawn. It could be discussed whether one should have acceptance criteria for both PTV and OARs. IROC Huston has 7% as acceptance for measurement points in PTV (end-to-end IMRT, head and neck phantom), but only gamma criterion for measurement points in the OAR [18, 19] . Even though it is important to verify the dose to OARs, it is normally more difficult to measure doses with high accuracy due to the dose gradients that normally appear in them. Also, small deviations in absolute dose can be large in percent. An alternative could be to set a percentage of the PTV dose for acceptance or to have higher acceptance limits for the OARs. This resulted in reduced calculated doses of approximately 2% for 3D-CRT and 1.5% for IMRT and VMAT plans (varying with depth in the phantom) and hence in improved agreement between measured and calculated doses. Thus, part of the deviations between measured and AAA calculated doses seem to stem from the use of a PMMA phantom together with the Varian default CT calibration curve. In an end-to-end dosimetric audit, it is essential that the patient CT calibration curve is used in TPS dose calculation as this is one of the factors desirable to control. The current finding suggests that use of a different plastic, closer to tissue in atomic composition than PMMA, would be a better choice.
One of the 3D-CRT audits had to be repeated twice before it was discovered that the out-of-tolerance results was a result of inclusion of couch rails in two of the radiation fields. This resulted in an underdosage of 12% in the salivary gland structures that was situated in the direct beam of these fields. This is an error that was discovered by the audit and is an error that can be present for patients as well. It should be mentioned that the audit irradiations were performed by physicists that do not normally treat patients.
In this pilot test, the dose planning process was chosen to follow certain criteria to be able to compare the results. For future measurements, the clinics should use their own treatment protocols.
Conclusions
The developed audit system based on lithium formate EPR and the logistics around it were found suitable for end-to-end audits. Dose values measured in the audit agreed with TPS calculated doses in the PTV to within ±5% for 3D CRT and ±7% for IMRT/VMAT for all participating clinics. Part of the found deviations between doses calculated by the AAA algorithm and measured ones most likely stems from the use of a PMMA phantom together with the clinically used CT calibration curve. A phantom made of a plastic more close to the composition of tissue than PMMA might thus be preferred in future audits. Our audit system provides dose verification at six measurement points in absolute dose units.
As a complement, the system could be extended to include gamma-analysis and dose profiles in 2D or 3D, using radiochromic film.
